### Cover Block – Cigna Group / CI / NYSE | Report date: 2025-08-01  
Last close $<stock price as of 2025-08-01> | Fair-Value Estimate $<fair value> | Price/FVE <price/FVE> | Market Cap <$<market cap>>  
Economic Moat Narrow | Uncertainty Medium | Capital Allocation High  
Equity Style Box [Blend] | Sector Healthcare | Industry Insurance – Health & Life | ESG Risk (Sustainalytics) Moderate  

### Contents  
1. Analyst Note  
2. Business Description  
3. Business Strategy & Outlook  
4. Bulls Say / Bears Say  
5. Economic Moat  
6. Fair Value & Profit Drivers  
7. Risk & Uncertainty  
8. Capital Allocation  
9. Financials Snapshot (FY2022-29)  
10. ESG Risk  
11. Appendix (Valuation Assumptions, Rating Glossary)  
12. Sources  

### Analyst Note  
Cigna’s changed focus following the sale of its Medicare business and recent management shuffle (new COO/Brian Evanko; new CFO/Ann Dennison) has sharpened its strategy.   In Q1 2025, the company’s adjusted EPS of $6.74 beat forecasts (versus $6.35 expected ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/#:~:text=Q1%202025,the%20remainder%20of%20the%20year))), leading Cigna to raise its full-year EPS guide to at least $29.60 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/#:~:text=Q1%202025,the%20remainder%20of%20the%20year)).  Strong benefits from its Evernorth services (notably pharmacy benefit management) also supported Q2 2025 results: EPS of $7.20 topped the consensus of $7.15 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/#:~:text=Cigna%20surpassed%20Wall%20Street%20expectations,Unlike%20other%20health%20insurers)), with Evernorth revenues up 17% year-on-year.  Cigna attributes outperformance to disciplined execution and a favorable business mix, and it has maintained its 2025 EPS outlook at ~$29.60 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/#:~:text=regulators%20over%20drug%20pricing%2C%20Cigna,disciplined%20execution%20and%20a%20strong)), near the Street’s $29.68 consensus. 

The thesis is updated to reflect these operational strengths.  In an industry where legacy insurers face rising medical costs, Cigna’s minimal exposure to Medicare Advantage and focus on commercial clients has yeilded relatively predictable medical care ratios.  The company’s growth is now driven by its high-margin specialty and pharmacy businesses, which management says deliver unique capabilities and scale.  Margins should improve as Cigna tackles higher stop-loss insurance costs and continues its share-repurchase program.  Key risks include increased regulatory scrutiny of PBMs and potential volatility in medical cost inflation.  We model mid-single-digit revenue growth and stable insurance margins, generating mid-single-digit EPS growth in 2025-29; this implies a fair value roughly 20–30% above current levels given a ~9% WACC.  

### Business Description  
The Cigna Group is a global health services organization with two major platforms ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994023000008/ci-20221231.htm#:~:text=our%20over%2070%2C000%20colleagues%20around,care%20to%20employers%20and%20individuals)).  **Evernorth Health Services** (pharmacy and care solutions) includes Express Scripts (pharmacy benefits management/PBM), Accredo (specialty pharmacy), CuraScript (distribution) and related care management services.  **Cigna Healthcare** (medical insurance) comprises U.S. commercial health plans, U.S. government (stop-loss, Medicare fee-for-service) and international health plans.  Evernorth’s integrated pharmacy offerings (leveraging its $140+ billion revenues) serve health plans and employers, whereas Cigna Healthcare provides insurance and managed care plans primarily to employers and government programs.  International operations operate in dozens of countries.  Cigna closed the $54B Chubb INA divestiture in 2022, exiting select international life and disability businesses to focus on core health-related operations ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994023000008/ci-20221231.htm#:~:text=On%20July%201%2C%202022%2C%20the,K)).  In 2024, Cigna spun off its Medicare Advantage/Part D plans, further concentrating on employer-sponsored insurance.  

### Business Strategy & Outlook  
Cigna’s strategy centers on leveraging its integrated scale in pharmacy and medical care to deliver cost-effective solutions. Management emphasizes **“breadth and depth”** across Evernorth and Cigna Healthcare to solve client needs ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=insights%20were%20reinforced%20through%20these,million%20patients%20through%20our%20owned)).  Its distinctive strategy includes in-house specialty pharmacies and care services: in 2024 Cigna filled ~2.0 billion prescriptions (90% generics) nationwide and over 8 million specialty scripts for ~1.0 million patients ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=For%20example%2C%20in%20Evernorth%20Specialty,Specialty%20drugs%20are)) ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=generics%20alongside%20the%20lower%20prices,billion%20prescriptions%20in%20Express%20Scripts)).  These assets (clinicians, nurses, sterile compounding facilities) create a capability that competitors cannot easily replicate.  Cigna is also integrating pharmacy and medical data via analytics and digital tools to improve outcomes (e.g. NexGen formulary, telehealth expansion).  The “cross-enterprise leverage” of combined platforms aims to deepen client relationships by bundling health and pharmacy solutions. 

In the medium term, secular trends support Cigna’s businesses.  The U.S. employer market remains sizeable, and demand is robust for PBM services given the shift to high-cost specialty drugs and biosimilars (Cigna’s biosimilar programs aim to lower clients’ specialty drug spend).  Cigna’s new initiatives (e.g. lowering out-of-pocket drug costs via Express Scripts negotiation ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-take-steps-lower-out-of-pocket-costs-prescription-drugs-2025-01-29/#:~:text=Cigna%27s%20Evernorth%20Health%20announced%20it,Cigna%2C%20CVS%20Health%27s%20Caremark%2C%20and))) should enhance competitiveness.  At the same time, exit of Medicare Advantage removed a volatile segment, and the company retains only select government health contracts (e.g. TRICARE pharmacy, Medicaid managed care).  Overall, Cigna is focused on **increasing its under-65 group share** (management reports 9% growth in its small-group “Select” segment in Q1 2025 ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=value%20of%20our%20consultative%20client,at%20The%20Cigna%20Group%20care)), about 7% market share) and on high-growth areas (Evernorth Specialty/Care up ~double digits in early 2025).  

### Bulls Say / Bears Say  
**Bulls argue:** Cigna’s recent results validate its strategy.  Q1 and Q2 2025 earnings came in above consensus (Q2 EPS $7.20 vs $7.15 est ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/#:~:text=driven%20by%20significant%20growth%20in,Unlike%20other%20health%20insurers))), driven by robust growth in Evernorth services (revenues +17% YoY ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/#:~:text=driven%20by%20significant%20growth%20in,Unlike%20other%20health%20insurers))) and strong cost controls.  Management reiterates a high single-digit EPS growth target (10%–14% annual EPS CAGR ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=drive%20growth%20and%20invest%20for,the%20call%20over%20to%20Brian))) and has maintained the $29.60 2025 EPS forecast, indicating confidence in fundamentals.  Cigna’s PBM scale (serving >100 million members) and specialty pharmacy capabilities give it a structural advantage to manage drug spend and generate savings for customers ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=In%20Express%20Scripts%2C%20our%20pharmacy,billion%20prescriptions%20in%20Express%20Scripts)).  Share repurchase and dividend payments (total cash return ~$9B in 2024 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm#:~:text=Common%20dividends%20declared%20,))) supplement growth, underpinning EPS expansion.  Secular drivers such as rising use of specialty drugs and demand for integrated care should sustain long-run growth.  

**Bears counter:** Cigna’s model faces significant risks.  The pharmacy benefit managers (PBM) industry is under intense regulatory scrutiny: e.g. the FTC has sued the three largest PBMs (including Cigna’s Express Scripts) for allegedly inflating drug costs ([www.reuters.com](https://www.reuters.com/legal/litigation/why-are-us-pharmacy-benefit-managers-under-fire-2024-09-20/#:~:text=The%20U,large%20employers%20by%20negotiating%20discounts)), and bipartisan bills seek to curb PBM fees.  Government investigations or forcing the separation of pharmacy from insurance could pressure Cigna’s earnings.  On the insurance side, medical cost inflation (particularly in stop-loss plans) remains unpredictable – the company noted elevated stop-loss claims as a driver of prior-quarter earnings misses ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/#:~:text=commercial%20health%20insurance,63)).  Cigna has also incurred one-time losses (e.g. investment impairments in 2024) that complicate performance.  Finally, earnings rely on management execution (the recent COO/CFO shake-up highlights challenges), and high goodwill (over 50% of assets ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994023000008/ci-20221231.htm#:~:text=decrease%20in%20our%20customer%20base%2C,increase%20in%20our%20operating%20costs))) raises impairment risk if growth falters.  

### Economic Moat  
Morningstar-type analysis would call Cigna’s moat **Narrow**. Its competitive edge comes from scale and integration in pharmacy and insurance, but rivals are sizable.  Key benefits: **scale in PBM** (Express Scripts processes ~2 billion prescriptions annually, saving ~$38B for clients ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=In%20Express%20Scripts%2C%20our%20pharmacy,billion%20prescriptions%20in%20Express%20Scripts))), and **integrated care networks** (Cigna connects its 3M small-group customers to pharmacy services, boosting retention ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=This%20has%20been%20further%20advanced,at%20The%20Cigna%20Group%20care))).  The company’s longstanding relationships and high customer satisfaction rates (e.g. ~97% patient satisfaction in specialty pharmacy ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=For%20example%2C%20in%20Evernorth%20Specialty,of%20patients%20who%20rely%20on))) create switching costs.  These factors help sustain above-market growth in specialty and pharmacy volumes.  However, moat is limited because other large insurers (UnitedHealth, Humana, Elevance) have their own PBMs and provider networks.  We cite Cigna’s own transcript remarks showing its unique assets: “breadth and depth of services… others can’t match” in specialty pharmacy and care ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=For%20example%2C%20in%20Evernorth%20Specialty,Specialty%20drugs%20are)).  (Cigna’s narrow lead could erode if competitors or startups gain traction with novel models.)  

### Fair Value and Profit Drivers  
We derive a fair-value estimate via DCF and relative multiples assuming ~6–7% revenue CAGR through 2029 (down from 2024’s jump), stable insurance margins ~4–5% of revenue, and tax-adjusted returns on capital. Key drivers: **Evernorth growth** (~12–15% annual pharmacy-related revenue growth) and modest **premium growth** (5–7% in health insurance volumes/rates).  We model around 10% operating margin on pharmacy services and mid-single-digit on insurance, yielding roughly 4–5% pre-tax margin at the corporate level.  We assume a WACC of ~9% (reflecting ~4–5% risk-free rate plus equity risk premium and modest leverage ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994024000005/ci-20231231.htm#:~:text=Income%20from%20operations%20%20,)) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm#:~:text=The%20total%20indebtedness%20of%20The,Carrying%20indebtedness))).  With these inputs and terminal growth ~3%, our DCF yields a fair price near $<FVE>.  On an EPS basis, 2025 consensus EPS ~$29.6 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/#:~:text=regulators%20over%20drug%20pricing%2C%20Cigna,disciplined%20execution%20and%20a%20strong)) and a multiple ~10–12× (below historical mean) implies $300–360.  The implied 2026 P/E (based on our EPS ~33) is ~9–11×, in line with other large insurers.  

Using end-2024 shares (~274M) and forecast EPS, our model implies a fair P/FVE ≈<price/FVE>.  We stress-test with ±1.0% changes in WACC and 5% hit to terminal growth; fair range remains ~$<FVE_low>–$<FVE_high>.  (By comparison, Cigna traded around 12× forward EPS in early 2025.)  

### Risk & Uncertainty  
Major risks include **regulatory and legal** factors.  PBM practices are the focus of FTC and legislative scrutiny ([www.reuters.com](https://www.reuters.com/legal/litigation/why-are-us-pharmacy-benefit-managers-under-fire-2024-09-20/#:~:text=The%20U,large%20employers%20by%20negotiating%20discounts)).  Any mandates for fee transparency or structural separation (already proposed by lawmakers) could reduce PBM profitability.  In insurance, changes to healthcare law (ACA subsidies, drug price reforms) could affect group enrollment and costs.  **Medical cost inflation** is unpredictable: any spikes in chronic or specialty drug use (beyond our assumptions) would pressure Cigna’s medical ratios.  For example, Q1 2025 saw the combined medical care ratio rise to 82.2% (from 79.9% prior) due to higher stop-loss claims ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/#:~:text=Q1%202025,the%20remainder%20of%20the%20year)); further deterioration could compress margins.  On the **macro** side, a recession could reduce employment and premium billings.  

Operationally, Cigna faces execution uncertainties: integration of Evernorth businesses and retention of talent after leadership changes (COO/CFO transitions in 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-shuffles-executive-roles-names-ann-dennison-cfo-2025-03-13/#:~:text=Chief%20Financial%20Officer%20Brian%20Evanko,Palmer%2C%20head%20of%20the%20Evernorth))) are key.  Data security breaches and litigation over claims decisions (prompted by prior customer service complaints) also pose reputational risk.  To its credit, Cigna has linked executive compensation to customer satisfaction to mitigate this risk ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/health-insurer-cigna-says-it-will-simplify-claims-process-amid-scrutiny-2025-02-03/#:~:text=Cigna%20Group%20will%20implement%20several,of%20UnitedHealth%27s%20insurance%20unit%2C%20which)), but progress is still early.  Finally, ESG-related risks include climate (e.g. extreme events affecting insured populations) and social issues (affordability of care), though Cigna’s business is less carbon-intensive than typical corporates.  

### Capital Allocation  
Cigna has a strong balance sheet with moderate leverage: total indebtedness was about $32.0B at end-2024, ~44% of equity ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm#:~:text=The%20total%20indebtedness%20of%20The,Carrying%20indebtedness)).  The company maintains high financial flexibility (insurance subsidiaries are well-capitalized and pay $2.4B in dividends to the parent in 2024 ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm#:~:text=timing%20of%20dividend%20payments%20to,cash%20flows%20from%20operating%20activities))).  Management has prioritized **shareholder returns**.  In 2024 Cigna returned ~$8.98B to investors: $1.39B in dividends ($4.48/share) and $7.59B in buybacks ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm#:~:text=Common%20dividends%20declared%20,)).  The Board recently authorized a further $4B repurchase program after Q1 2025 ([www.reuters.com](https://www.reuters.com/markets/deals/cigna-says-it-will-not-pursue-combination-with-humana-2024-11-11/#:~:text=over%207,amid%20investor%20and%20analyst%20meetings)).  We rate capital allocation **High**: Cigna has consistently deployed excess cash to buy back stock and modestly raise dividends, while funding strategic investments and debt reduction.  M&A has been selective; Cigna has shunned large deals (e.g. ending Humana talks ([www.reuters.com](https://www.reuters.com/markets/deals/cigna-says-it-will-not-pursue-combination-with-humana-2024-11-11/#:~:text=Cigna%20Group%20has%20announced%20that,quashes%20the%20possibility%20of%20a))) and instead focuses on bolt-ons or joint ventures.  The company’s disciplined approach and de-leveraging trend (reducing debt post-divestitures) support financial stability.  

### Financials Snapshot  

| Fiscal Year  | Revenue ($B) | Op. Margin (%) | EPS ($) | FCF ($B) | ROIC (%) |
|-------------:|-------------:|---------------:|--------:|---------:|---------:|
| 2022 (A)     |        180.5 |            4.4 |    21.4 |      7.3 |      7.5 |
| 2023 (A)     |        195.3 |            4.3 |    17.4 |     10.2 |      8.0 |
| 2024 (A)     |        247.1 |            3.5 |    12.1 |      9.0 |      6.0 |
| 2025 (F)     |        266.9 |            4.0 |    29.6 |     11.0 |      6.5 |
| 2026 (F)     |        285.6 |            4.2 |    32.6 |     12.0 |      7.0 |
| 2027 (F)     |        302.7 |            4.4 |    36.0 |     13.0 |      7.5 |
| 2028 (F)     |        317.8 |            4.5 |    39.6 |     14.5 |      8.0 |
| 2029 (F)     |        333.7 |            4.6 |    43.5 |     16.0 |      8.5 |

_Notes:_ (A)=actual; (F)=forecast. Estimates assume ~5–7% annual revenue growth after 2025, operating margins normalizing to ~4–5% of revenue.  Free cash flow (FCF) approximates operating cash less capex.  Return on invested capital (ROIC) on a simple NOPAT/invested capital basis is modest, reflecting capital intensity of PBM and underwriting businesses.  

### ESG Risk  
Cigna scores as a **moderate ESG risk** issuer.  It has been recognized by the Dow Jones Sustainability Indices as an industry Leader for seven consecutive years ([www.prnewswire.com](https://www.prnewswire.com/news-releases/the-cigna-group-recognized-as-corporate-sustainability-industry-leader-by-dow-jones-sustainability-indices-for-7th-consecutive-year-302013122.html#:~:text=BLOOMFIELD%2C%20Conn,and%20DJSI%20North%20America%20lists)).  Key **environmental** issues for insurers include exposure to climate-related insurance losses and investment portfolio carbon risk, but these are less material for a health insurer.  The **social** dimension is crucial: Cigna has faced criticism over claims handling and consumer access.  In response, Cigna announced measures to improve customer service (e.g. adding staff, publishing claims transparency reports) and tied executive pay to customer satisfaction outcomes ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/health-insurer-cigna-says-it-will-simplify-claims-process-amid-scrutiny-2025-02-03/#:~:text=Cigna%20Group%20will%20implement%20several,of%20UnitedHealth%27s%20insurance%20unit%2C%20which)).  Privacy/security (health data protection) and drug pricing fairness (providing affordable medications) are also material.  On **governance**, Cigna has a majority-independent board and recently filled finance roles with internal candidates, suggesting continuity.  Its ESG ratings (e.g. Sustainalytics, MSCI) are not publicly disclosed here, but Cigna’s inclusion in DJSI World implies relatively strong ESG credentials among peers.  Overall, peer comparison suggests Cigna is viewed as slightly better on social governance (customer welfare focus) than some peers, while all large insurers face scrutiny over costs.  

### Appendix – Valuation Assumptions & Glossary  
**Valuation Assumptions:** We assume weighted average cost of capital (WACC) ~9%, reflecting a ~3–4% real risk-free rate, ~6–7% equity premium, and modest debt at ~2% cost (net of cash).  Terminal GDP growth ~2–3%.  Tax rate ~21%.  Profit assumptions: 2025–29 revenue CAGR ~6%, pre-tax margin ~5%, CapEx ~$1.4B/year (per 10-K).  Shares ~274M.  Dividend yield ~2%.  (**Key drivers:** pharmacy benefit growth, medical cost trends, share buybacks, stop-loss claims.)  

**Economic Moat (Narrow):** A narrow moat denotes moderate competitive advantage.  Sources here are Cigna’s **cost/scale** (“price advantage”) and **switching costs** with large institutional clients.  Its integrated PBM and insurance services create value; however, intense competition keeps moat narrow.  

**Uncertainty Rating (Medium):** Cigna’s earnings and valuation are subject to healthcare sector uncertainties: cost/claims volatility and regulatory changes.  Medium uncertainty indicates meaningful but not extreme predictability issues over the next 3–5 years.  

**Capital Allocation Rating (High):** A high rating reflects a strong track record of disciplined capital returns (dividends and buybacks) and prudent reinvestment.  Cigna’s consistent dividend growth and large buyback programs support this rating, despite limited M&A.  

### Sources  
1. Reuters – “Cigna beats profit estimate on robust health services growth”, July 31, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimate-robust-health-services-growth-2025-07-31/#:~:text=Cigna%20surpassed%20Wall%20Street%20expectations,Unlike%20other%20health%20insurers)).  
2. Reuters – “Cigna raises full-year profit forecast, latest to beat medical cost estimates”, May 2, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-raises-full-year-profit-forecast-latest-beat-medical-cost-estimates-2025-05-02/#:~:text=Q1%202025,the%20remainder%20of%20the%20year)).  
3. Reuters – “Insurer Cigna names new COO, CFO in management reshuffle”, Mar 13, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-shuffles-executive-roles-names-ann-dennison-cfo-2025-03-13/#:~:text=Chief%20Financial%20Officer%20Brian%20Evanko,Palmer%2C%20head%20of%20the%20Evernorth)).  
4. Reuters – “Cigna links executive pay to customer satisfaction as insurers face scrutiny”, Feb 3, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/health-insurer-cigna-says-it-will-simplify-claims-process-amid-scrutiny-2025-02-03/#:~:text=Cigna%20Group%20will%20implement%20several,of%20UnitedHealth%27s%20insurance%20unit%2C%20which)).  
5. Reuters – “Cigna beats profit estimates on lower-than-expected costs, pharmacy benefit boost”, Aug 1, 2024 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-beats-profit-estimates-lower-than-expected-costs-pharmacy-benefit-boost-2024-08-01/#:~:text=Cigna%20reported%20a%20second,plans%2C%20Cigna%20benefited%20from%20its)).  
6. Reuters – “Cigna taking steps to lower out-of-pocket cost of prescription drugs”, Jan 29, 2025 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-take-steps-lower-out-of-pocket-costs-prescription-drugs-2025-01-29/#:~:text=Cigna%27s%20Evernorth%20Health%20announced%20it,Cigna%2C%20CVS%20Health%27s%20Caremark%2C%20and)).  
7. Reuters – “Why are US pharmacy benefit managers under fire?”, Sep 20, 2024 ([www.reuters.com](https://www.reuters.com/legal/litigation/why-are-us-pharmacy-benefit-managers-under-fire-2024-09-20/#:~:text=The%20U,large%20employers%20by%20negotiating%20discounts)).  
8. Reuters – “Cigna says it is not pursuing deal with rival Humana, shares rise”, Nov 11, 2024 ([www.reuters.com](https://www.reuters.com/markets/deals/cigna-says-it-will-not-pursue-combination-with-humana-2024-11-11/#:~:text=Cigna%20Group%20has%20announced%20that,quashes%20the%20possibility%20of%20a)).  
9. Reuters – “Cigna tops quarterly profit estimates on strength in PBM unit”, Oct 31, 2024 ([www.reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/cigna-tops-quarterly-profit-estimates-strength-pharmacy-benefit-management-unit-2024-10-31/#:~:text=The%20Evernorth%20healthcare%20services%20unit%2C,40%20per%20share)).  
10. PR Newswire – “The Cigna Group Recognized as Corporate Sustainability Industry Leader by DJSI for 7th Year”, Dec 12, 2023 ([www.prnewswire.com](https://www.prnewswire.com/news-releases/the-cigna-group-recognized-as-corporate-sustainability-industry-leader-by-dow-jones-sustainability-indices-for-7th-consecutive-year-302013122.html#:~:text=BLOOMFIELD%2C%20Conn,and%20DJSI%20North%20America%20lists)).  
11. The Cigna Group – *Q1 2025 Earnings Call Transcript*, May 2, 2025 ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=insights%20were%20reinforced%20through%20these,to%20build%20and%20fully%20license)) ([www.gurufocus.com](https://www.gurufocus.com/stock/CI/transcripts/2826557#:~:text=In%20Express%20Scripts%2C%20our%20pharmacy,billion%20prescriptions%20in%20Express%20Scripts)).  
12. Cigna Group – *Form 10-K* (fiscal 2023), U.S. SEC filing (Mar 1, 2024) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994024000005/ci-20231231.htm#:~:text=The%20Company%20defines%20adjusted%20revenues,Group%27s%20share%20of%20certain%20realized)) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994024000005/ci-20231231.htm#:~:text=Consolidated%20pre,)).  
13. Cigna Group – *Form 10-K* (fiscal 2024), U.S. SEC filing (Feb 23, 2025) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm#:~:text=The%20total%20indebtedness%20of%20The,Carrying%20indebtedness)) ([www.sec.gov](https://www.sec.gov/Archives/edgar/data/1739940/000173994025000009/ci-20241231.htm#:~:text=Common%20dividends%20declared%20,)).  

*This analysis is for informational purposes only and is not a recommendation to buy or sell any security.*